Over the years, cancer has continued to be a leading global health threat, prompting researchers to explore advanced therapies that go beyond traditional treatments like chemotherapy and radiotherapy. Among these advanced therapies, gene therapy and immunotherapy have shown significant promise in treating cancer by either altering genetic makeup or stimulating the immune system. However, their clinical applications face significant obstacles such as poor drug delivery, rapid degradation, and immune system clearance. Hybrid nanocarriers have emerged as a transformative development in modern precision oncology, enabling the co-delivery of gene therapy and immunotherapy agents in a highly targeted manner to address the persistent limitations of traditional cancer treatments. This review focuses on hybrid nanocarrier systems specifically engineered for co-delivery applications and critically evaluates when and how these multifunctional platforms outperform conventional single-modality or non-hybrid formulations. We compare key hybrid architectures in terms of payload compatibility, pharmacokinetics, immune modulation, and translational readiness, and examine the influence of tumor microenvironmental characteristics on their therapeutic performance. Particular emphasis is placed on stimuli-responsive designs, biomimetic surface engineering, and artificial intelligence–assisted optimization as emerging strategies to enhance co-delivery efficacy. By synthesizing current evidence and identifying key scientific and manufacturing gaps, this review aims to provide a practical foundation for advancing hybrid nanocarriers from laboratory development to clinically meaningful, personalized cancer therapies.

The human immunodeficiency virus (HIV) epidemic in Sub-Saharan Africa (SSA) disproportionately affects adolescent girls and young women (AGYW), who face a risk of infection up to three times higher than their male peers. SSA accounts for 65% of the global HIV burden, with Eastern and Southern Africa showing particularly high rates. The aim of this study was to examine the persistent gender disparities in HIV infections, focusing on the biological, social, and structural drivers of AGYW’s heightened vulnerability. Biological factors such as immature cervical development and hormonal influences intersect with social determinants, including gender inequality, cultural norms, and economic pressures. These factors reduce young women’s ability to negotiate safer sexual practices and increase reliance on transactional relationships with older partners. Despite initiatives such as determined, resilient, empowered, AIDS-free, mentored, and safe (DREAMS) and Education Plus, barriers such as stigma, gender-based violence, and limited access to youth-friendly sexual and reproductive health services persist. Addressing these disparities requires multi-level, gender-responsive interventions that strengthen healthcare access, expand female-controlled prevention options, and promote education and economic empowerment. Closing the gender gap in HIV outcomes will demand sustained policy commitment and community engagement tailored to the needs of adolescent girls in SSA.

Sepsis-induced liver failure remains a serious and often under-recognized complication of abdominal sepsis. Clinical reports suggest that liver dysfunction develops in a substantial proportion of these patients, and once failure ensues, mortality rises sharply. Despite progress in antimicrobial therapy and critical care support, there is still no therapy that directly halts or reliably reverses septic liver injury. Systemic drug administration frequently underperforms in this setting. Hepatic drug accumulation becomes unpredictable, pharmacokinetics shift, and immune dysregulation further complicates therapeutic control. Nanotechnology-based delivery systems have attempted to address these shortcomings by improving drug stability and circulation time. Yet their behavior under septic conditions remains inconsistent. This inconsistency may reflect a deeper issue: most carriers are engineered under relatively stable physiological assumptions that do not hold during systemic inflammation. Biomimetic platforms, particularly those derived from erythrocyte membranes, offer a different conceptual entry point. Rather than merely evading immune recognition, erythrocyte-based systems interact naturally with hepatic clearance pathways. During sepsis, erythrocyte turnover appears to accelerate, and macrophage-mediated clearance in the liver intensifies. This shift, while pathologic, may present a therapeutic opportunity. In this review, we examine current liver-targeted delivery strategies for sepsis-induced liver failure and critically assess the underexplored role of erythrocyte ghost-based systems. We discuss how sepsis-specific pathophysiological changes reshape carrier biodistribution, identify translational constraints, and propose design considerations for inflammation-adaptive biomimetic platforms. By reconsidering hepatic clearance not solely as a pharmacokinetic barrier but as a potential delivery route, we outline a disease-aligned approach to nanomedicine design in septic organ failure.

The multifaceted impact of economic hardship, insecurity, and flooding on access to antiretroviral therapy (ART) among people living with HIV/AIDS (PLHIV)

Type 2 diabetes has always remained one of the perturbing chronic diseases which cause numerous mortality rates globally. Proper and recommended dieting as well as lifestyle modification has been one of the approach in the treatment of Type 2 Diabetes Mellitus. Adherence to these nutritional approaches from several studies have shown positive results in the delay of the progression of these disease. More so, an increased risk for developing type 2 diabetes is associated with overweight and obesity, physical inactivity and high intake of saturated fats. Therefore, recommended nutritional diets and regular physical activity remains the part and parcel of the management of Type 2 Diabetes Mellitus.